文献速递心力衰竭与心肌病

S100A1ct:源自S100A1蛋白的合成肽改善临床前心衰模型的心脏功能与生存

S100A1ct: A Synthetic Peptide Derived From S100A1 Protein Improves Cardiac Performance and Survival in Preclinical Heart Failure Models.
PubMed 文献 · Circulation · 2024-11-21

本研究开发了源自S100A1蛋白C端α螺旋(残基75-94)的合成细胞穿透肽S100A1ct,通过计算模拟、体外生化与心肌细胞功能评估及小/大动物心衰模型验证。S100A1ct具有正性肌力和抗心律失常特性,可剂量依赖性增强心肌细胞钙循环并防止β肾上腺素能受体触发的钙失衡,改善射血分数降低的临床前心衰模型的收缩功能和生存。

要点

  • S100A1ct通过靶向SERCA2a和RyR2增强心肌细胞钙循环,发挥正性肌力和抗心律失常作用。
  • 在射血分数降低的临床前心衰模型中,S100A1ct全身给药改善收缩功能和生存。
  • 心肌细胞靶向肽标签修饰的cor-S100A1ct进一步增强了生物学和治疗效力。

核心结论

  • S100A1ct是开发针对射血分数降低的心力衰竭的新型肽类治疗药物有前景的先导化合物。

研究设计与样本

  • 研究采用从计算分子建模、体外生化与分子试验、离体啮齿类和人类心肌细胞功能评估到小和大动物心脏疾病模型的体内安全性和有效性研究的整合转化研究流程。

主要发现

  • S100A1ct被表征为一种细胞穿透肽,在体外和体内的正常和衰竭心肌中具有正性肌力和抗心律失常特性。
  • S100A1ct全身给药后,在射血分数降低的临床前心衰模型中转化为收缩性能改善和生存率提高。
  • S100A1ct通过靶向SERCA2a和RyR2活性,快速且持续地剂量依赖性增强心肌细胞钙循环,并防止β肾上腺素能受体触发的钙失衡。
  • 建模提示肽与肌浆网钙泵的跨膜段相互作用,与S100A1ct介导的SERCA2a活性增强一致。
  • 将心肌细胞靶向肽标签整合到S100A1ct中(cor-S100A1ct)进一步增强了其在体外和体内的生物学和治疗效力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The EF-hand Ca2+ sensor protein S100A1 has been identified as a molecular regulator and enhancer of cardiac performance. The ability of S100A1 to recognize and modulate the activity of targets such as SERCA2a (sarcoplasmic reticulum Ca2+ ATPase) and RyR2 (ryanodine receptor 2) in cardiomyocytes has mostly been ascribed to its hydrophobic C-terminal α-helix (residues 75-94). We hypothesized that a synthetic peptide consisting of residues 75 through 94 of S100A1 and an N-terminal solubilization tag (S100A1ct) could mimic the performance-enhancing effects of S100A1 and may be suitable as a peptide therapeutic to improve the function of diseased hearts. METHODS: We applied an integrative translational research pipeline ranging from in silico computational molecular modeling and in vitro biochemical molecular assays as well as isolated rodent and human cardiomyocyte performance assessments to in vivo safety and efficacy studies in small and large animal cardiac disease models. RESULTS: We characterize S100A1ct as a cell-penetrating peptide with positive inotropic and antiarrhythmic properties in normal and failing myocardium in vitro and in vivo. This activity translates into improved contractile performance and survival in preclinical heart failure models with reduced ejection fraction after S100A1ct systemic administration. S100A1ct exerts a fast and sustained dose-dependent enhancement of cardiomyocyte Ca2+ cycling and prevents β-adrenergic receptor-triggered Ca2+ imbalances by targeting SERCA2a and RyR2 activity. In line with the S100A1ct-mediated enhancement of SERCA2a activity, modeling suggests an interaction of the peptide with the transmembrane segments of the sarcoplasmic Ca2+ pump. Incorporation of a cardiomyocyte-targeting peptide tag into S100A1ct (cor-S100A1ct) further enhanced its biological and therapeutic potency in vitro and in vivo. CONCLUSIONS: S100A1ct is a promising lead for the development of novel peptide-based therapeutics against heart failure with reduced ejection fraction.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Kehr D, Ritterhoff J, Glaser M, et al. S100A1ct: A Synthetic Peptide Derived From S100A1 Protein Improves Cardiac Performance and Survival in Preclinical Heart Failure Models. Circulation. 2024. PMID: 39569500. doi:10.1161/CIRCULATIONAHA.123.066961

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。